Placeholder

Fostering interactions among industry, investors, government, and academia

2022 Novo Nordisk Golden Ticket

DEADLINE EXTENDED

Is your next step to accelerate your start-up becoming a part of LabCentral´s vibrant community and access to premium lab equipment? Then this might be an opportunity for you. Novo Nordisk's call for two Golden Tickets to LabCentral is open now. Each ticket covers the cost of one bench for one year.

Proposals in the fields of metabolism, fibrosis, inflammation – as well as technology or biology platforms, including computational and systems biology, artificial intelligence and machine learning are of high interest ot Novo Nordisk. 

Applications can be submitted via: CZYI@novonordisk.com or SBBJ@novonordisk.com

By submitting an application, you agree to the Terms and Conditions. For more information and to read the full list of requirements please visithttps://labcentral.site/novon 

Timeline 

Open Call Closes: 12pm Eastern Standard Time on August 7, 2022

Semi-finalists informed by August 28, 2022

Finalists informed by September 30, 2022

Golden Ticket Award Show - presentation by finalist and selection of winners will take place in September or October date TBD in Cambridge. 

About Novo Nordisk in the US

Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes live longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, haemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, thing long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk.us